health
Merck CEO says new pipeline is built to offset Keytruda's eventual patent expiration
Merck CEO Rob Davis said the drugmaker has evolved beyond Keytruda, with more than 20 potential blockbuster launches over the next five years.
TL;DR
- Merck's CEO Rob Davis announced the company's transformation beyond reliance on Keytruda.
- The company plans to launch over 20 new products in the next five years, with potential blockbuster status.
- Merck has invested heavily in internal research and $65 billion in business development over five years.
- New products highlighted include Winrevair for a lung disease and Lipfendra for cholesterol.
- An injectable version of Keytruda, Keytruda QLEX, has also been introduced.
- Merck's shares have outperformed the pharmaceutical ETF over the past year.